Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC cut its position in shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 66.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,561 shares of the biopharmaceutical company’s stock after selling 24,350 shares during the period. Guggenheim Capital LLC’s holdings in Intercept Pharmaceuticals were worth $772,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Raymond James & Associates acquired a new position in Intercept Pharmaceuticals during the fourth quarter valued at approximately $1,991,000. Macquarie Group Ltd. boosted its position in Intercept Pharmaceuticals by 95.4% during the fourth quarter. Macquarie Group Ltd. now owns 9,768 shares of the biopharmaceutical company’s stock valued at $571,000 after purchasing an additional 4,768 shares during the last quarter. HL Financial Services LLC boosted its position in Intercept Pharmaceuticals by 12.8% during the first quarter. HL Financial Services LLC now owns 12,016 shares of the biopharmaceutical company’s stock valued at $739,000 after purchasing an additional 1,359 shares during the last quarter. Oppenheimer & Co. Inc. boosted its position in Intercept Pharmaceuticals by 32.4% during the first quarter. Oppenheimer & Co. Inc. now owns 6,480 shares of the biopharmaceutical company’s stock valued at $399,000 after purchasing an additional 1,585 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in Intercept Pharmaceuticals by 23.0% during the first quarter. SG Americas Securities LLC now owns 35,087 shares of the biopharmaceutical company’s stock valued at $2,159,000 after purchasing an additional 6,556 shares during the last quarter. 66.34% of the stock is currently owned by hedge funds and other institutional investors.

ICPT has been the subject of several recent research reports. Wedbush increased their price target on Intercept Pharmaceuticals from $203.00 to $217.00 and gave the company an “outperform” rating in a research report on Monday, August 6th. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th. Cantor Fitzgerald set a $69.00 price target on Intercept Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, August 2nd. ValuEngine raised Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 2nd. Finally, Zacks Investment Research raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $105.00 price target for the company in a research report on Tuesday, July 10th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $117.67.

Intercept Pharmaceuticals opened at $113.50 on Friday, according to Marketbeat Ratings. Intercept Pharmaceuticals Inc has a twelve month low of $51.05 and a twelve month high of $121.92. The company has a current ratio of 6.51, a quick ratio of 4.58 and a debt-to-equity ratio of 2.48.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($2.58) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.83) by $0.25. The firm had revenue of $43.58 million for the quarter, compared to the consensus estimate of $41.26 million. Intercept Pharmaceuticals had a negative return on equity of 614.15% and a negative net margin of 215.30%. The business’s quarterly revenue was up 41.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($3.46) EPS. equities analysts expect that Intercept Pharmaceuticals Inc will post -10.86 earnings per share for the current fiscal year.

Intercept Pharmaceuticals Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

See Also: Leveraged Buyout (LBO) Explained

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply